Biogen Inc.

Please stand by, we're about to begin. Good morning, my name is Jess and I will be your conference operator today.

At this time, I would like to welcome everyone to the Biogen second quarter 2026 earnings call and business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star one on your telephone keypad. Please limit yourself to one question to allow other participants time for questions. If you require any further follow up, you may press star one again to rejoin the queue. Today's conference is being recorded. Thank you. I would now like to turn the conference over to Mr. Tim Power, head of investor relations. Mr. Power, you may begin your conference.

Thanks, Jess, and good morning, everyone. Welcome to Biogen's second quarter 2026 earnings call. During this call, we'll make forward-looking statements which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, which I encourage you to review. Our earnings release and other documents related to our results, as well as reconciliations between GAAP and non-GAAP results discussed in this call, can be found in the investor section of Biogen.com. We've also posted slides to our website that will be used during the call. On today's call, I'm joined by our President and Chief Executive Officer, Chris Viehbacher, Dr. Priya Singhal, Head of Development, and Robin Kramer, our Chief Financial Officer. Alisha Alaimo, President of North America, will also be available for the Q&A section of the call. We'll make some opening comments and we'll move to Q&A. And to allow us to get through as many questions as possible, we kindly ask that you limit yourself to just one question.